logo
No red flags in one doctor's 72,000 scripts, cannabis giant insists

No red flags in one doctor's 72,000 scripts, cannabis giant insists

Staley said Montu was 'proud of [its] sector-leading approach', claiming a mandatory 20-minute nurse consultation for every patient.
Meanwhile, the federal medical regulator has stepped up investigations into doctors prescribing cannabis. More than 20 practitioners are under review for potentially putting profit ahead of patient safety.
And discussion of the issue has prompted a prominent drug policy reform group to say broader cannabis reform is urgently needed, to allow 'carefully regulated adult-use cannabis access' that sits outside the medical system.
This masthead revealed high-volume prescribing at Montu using leaked company documents that showed just eight of the company's doctors together issued 245,109 scripts in the two years to June 30 this year, an average of 295 scripts per doctor for a standard five-day working week.
The revelations prompted alarm among medical experts and health officials about the scale and speed of prescribing in Australia's booming cannabis sector.
Loading
Federal Health Minister Mark Butler responded by warning of 'unscrupulous and possibly unsafe behaviour' in the industry.
Asked on Monday about the 72,000 scripts, Butler said that while medicinal cannabis had provided 'a lot of relief to a lot of people, from kids with epilepsy right up to adults with really hard-to-treat mental health issues', there were 'some business practices that have emerged that are, frankly, unsafe and certainly unscrupulous'.
He said he had asked regulators to advise all health ministers 'on how to regulate this industry in a more safe way.'
The Australian Health Practitioner Regulation Agency oversees doctors, nurses and other practitioners nationally. It has taken formal action against 57 practitioners over medicinal cannabis prescribing, and a rise in complaints from patients and health professionals led it to identify more than 20 practitioners, most of them red-flagged due to high patient and prescription numbers.
An AHPRA spokesperson said these clinicians must justify their prescribing practices or face regulatory action.
Montu, owner of the Alternaleaf brand, operates a vertically integrated model; its 120 nurses and doctors conduct telehealth consultations and its pharmacy arm dispenses products, including its in-house brands 'Circle' and 'Sundaze'.
Since medical cannabis was legalised in 2016, the company's 'closed loop' model has put it at the forefront of the industry's rapid expansion. Montu's revenue grew from $103,000 in 2020 to $263 million in 2024.
Its claims that its clinics are not high turnover are at odds with the experience of 10 of its former clinicians, speaking on background, who told this masthead that consultations were often extremely brief.
One leaked document showed consultations were scheduled for 10 minutes, and clinicians said they were often far shorter.
'When you're starting to do five-minute sessions, you're literally not even talking to the patient,' one former prescribing doctor said in Monday's story. 'You're just giving them cannabis.'
Concerns about the structure of the medicinal cannabis industry are also being raised by public health bodies.
Dr Jake Dizard, director of research at the Penington Institute, said medicinal cannabis had delivered benefits to many but warned that the system was now being pushed well beyond its original intent.
Loading
'Too often, unscrupulous doctors and companies are putting profits over patients' interests,' he said.
Dizard said demand for cannabis in Australia was 'high and persistent, so leaving the medical system as the only legal access point creates bad incentives to expand client volume at the expense of quality care'.
The ability of companies to both prescribe and dispense cannabis created conflicts of interest and transparency problems, he said.
'Medical cannabis shouldn't be an opaque industry where big companies both prescribe and dispense their own products.'
Loading
Dizard said broader cannabis reform might ultimately be necessary to relieve pressure on the medical system.
'Governments should embrace comprehensive cannabis legalisation and strict regulation to take pressure off the medical cannabis system. Separating out medicinal and non-medicinal cannabis and establishing carefully regulated adult-use cannabis access is an essential part of the solution.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Labor vows to ‘fight' as Trump threatens pharma tariffs
Labor vows to ‘fight' as Trump threatens pharma tariffs

Perth Now

time5 days ago

  • Perth Now

Labor vows to ‘fight' as Trump threatens pharma tariffs

Health Minister Mark Butler says the Albanese government will 'fight for the PBS'. Martin Ollman / NewsWire Health Minister Mark Butler says the Albanese government will 'fight for the PBS'. Martin Ollman / NewsWire Credit: News Corp Australia The Albanese government is vowing to 'fight for the PBS' as Donald Trump tries to strongarm drugmakers into moving production to the US. The Pharmaceutical Benefits Scheme (PBS) is a list of federally subsidised medicines and a prized Labor invention. Health Minister Mark Butler last month introduced legislation that, if passed, would cap PBS-listed medicines at $25 from January 1, 2026. Aside from subsidising medicines, the scheme also compels firms to negotiate prices with the federal government, which helps keep products affordable. Celebrated as a cornerstone of the healthcare system in Canberra, the scheme is denounced by pharmaceutical lobbyists in Washington, who claim Australia is 'freeloading on American innovation'. One group, Pharmaceutical Research and Manufacturers of America (PhRMA), has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. But Anthony Albanese, Mr Butler and other ministers have ruled out budging on the PBS. 'We'll fight for our PBS and fight for the jobs of Australian manufacturers here,' Mr Butler told the ABC on Friday, noting most production is in Melbourne. Pharmaceutical exports to the US totalled north of $2bn in 2024, making it the biggest foreign market for Australian producers. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous medical items, such as bandages. Though, as Mr Butler noted, the US still exported more to Australia and did so without tariffs. 'We have zero tariffs on those imports that we take from America companies,' he said. 'We're making the case that should continue in reverse. 'We should be able to continue to export our terrific blood and plasma products and medicines to Americans without what might be a 250 per cent tariff.' Camera Icon Health Minister Mark Butler says the Albanese government will 'fight for the PBS'. Martin Ollman / NewsWire Credit: News Corp Australia For the moment, Mr Trump's concern with the sector appears to be largely driven by bringing down prices in the US rather than punishing allies for having cheaper medicines. Last week, he wrote to 17 major pharmaceutical companies demanding they lower their prices for American consumers to bring them in line with prices overseas. A Rand Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to Mr Trump, is making pharmaceuticals in the US. Mr Trump's 250 per cent tariff threat was a warning shot to firms, but one that, if realised, would hit producers Down Under hard.

Labor vows to ‘fight' as Trump threatens pharma tariffs
Labor vows to ‘fight' as Trump threatens pharma tariffs

News.com.au

time5 days ago

  • News.com.au

Labor vows to ‘fight' as Trump threatens pharma tariffs

The Albanese government is vowing to 'fight for the PBS' as Donald Trump tries to strongarm drugmakers into moving production to the US. The Pharmaceutical Benefits Scheme (PBS) is a list of federally subsidised medicines and a prized Labor invention. Health Minister Mark Butler last month introduced legislation that, if passed, would cap PBS-listed medicines at $25 from January 1, 2026. Aside from subsidising medicines, the scheme also compels firms to negotiate prices with the federal government, which helps keep products affordable. Celebrated as a cornerstone of the healthcare system in Canberra, the scheme is denounced by pharmaceutical lobbyists in Washington, who claim Australia is 'freeloading on American innovation'. One group, Pharmaceutical Research and Manufacturers of America (PhRMA), has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. But Anthony Albanese, Mr Butler and other ministers have ruled out budging on the PBS. 'We'll fight for our PBS and fight for the jobs of Australian manufacturers here,' Mr Butler told the ABC on Friday, noting most production is in Melbourne. Pharmaceutical exports to the US totalled north of $2bn in 2024, making it the biggest foreign market for Australian producers. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous medical items, such as bandages. Though, as Mr Butler noted, the US still exported more to Australia and did so without tariffs. 'We have zero tariffs on those imports that we take from America companies,' he said. 'We're making the case that should continue in reverse. 'We should be able to continue to export our terrific blood and plasma products and medicines to Americans without what might be a 250 per cent tariff.' For the moment, Mr Trump's concern with the sector appears to be largely driven by bringing down prices in the US rather than punishing allies for having cheaper medicines. Last week, he wrote to 17 major pharmaceutical companies demanding they lower their prices for American consumers to bring them in line with prices overseas. A Rand Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to Mr Trump, is making pharmaceuticals in the US. Mr Trump's 250 per cent tariff threat was a warning shot to firms, but one that, if realised, would hit producers Down Under hard.

Australian news and politics live: Health Minister Mark Butler vows to defends Australia's PBS amid US threats
Australian news and politics live: Health Minister Mark Butler vows to defends Australia's PBS amid US threats

West Australian

time6 days ago

  • West Australian

Australian news and politics live: Health Minister Mark Butler vows to defends Australia's PBS amid US threats

Scroll down for the latest news and updates. Health Minister Mark Butler says the Australian Government is committed to defending both the Pharmaceutical Benefits Scheme (PBS) and the jobs supported by local drug manufacturers. With growing pressure from the US threatening tariffs as high as 250 per cent on pharmaceutical exports, Mr Butler insists Australia will fight to maintain its affordable medicines system while protecting its exporters. 'We'll fight for our PBS and fight for the jobs that Australian manufacturers here, particularly in Melbourne, down in Melbourne CSL, have provided to Australian families for years,' he told Sunrise on Friday morning. 'Exporting great medicines, blood and plasma products to the United States under the US free trade agreement. 'The US exports more pharmaceuticals to Australia. We have zero tariffs on those imports that we take from American companies. We're making the case that should continue in reverse. 'We should be able to continue to export our terrific blood and plasma products and medicines to Americans without what might be a 250 per cent tariff. Not just on Australia but on every country around the world seeking to export pharmaceuticals to the Americans.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store